CytomX About Probody Therapeutics Pipeline Partners Investors & News Culture & Careers Probody Therapeutics. Anti-Cancer! Outsmarting cancer Probody® therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity —and toxicity— in healthy tissue. When Probody therapeutics encounter active proteases near tumor tissue, their substrates are designed to be cleaved, removing their masks and activating them to bind to their tumor targets, potentially turning the disease against itself. With Probody therapeutics, we have the potential to: Create or widen the therapeutic window—the range of a drug’s dosage that is effective without causing unacceptable toxicity Enable new combinations previously not possible due to toxicities Expand the universe of drug targets previously considered “undruggable” due to the target’s presence on health tissues Make new treatment options possible, so that more patients can benefit More information about protease biology can be found in our fact sheet. Current treatments suffer from limited therapeutic window % of patients responding Dose of drug Contact Us 151 Oyster Point Blvd, Suite 400 South San Francisco, CA 94080-1913 Offices: 650-515-3185 Fax: 650-351-0353 Share Linkedin Twitter © 2021 CytomX Therapeutics, Inc. | PROBODY, CYTOMX, and our corporate logo are U.S. registered trademarks of CytomX Therapeutics, Inc. IHZ is a trademark of CytomX Therapeutics, Inc. All other brands and trademarks referenced herein are the property of their respective owners. About Overview Vision & Mission Our Values Executive Team Board of Directors Scientific Advisory Board Contact Us Probody Therapeutics Our Probody Approach How Probody Therapeutics Work A Versatile Platform Scientific Publications & Presentations Pipeline Advancing a Pipeline Lead Candidates Clinical Trials Access for HCPs/Patients Partners Opportunities Current Partners Investors & News Corporate Profile Press Releases Events & Presentations Scientific Publications Corporate Governance Stock Information Financial & Filings Analyst Coverage Investor Resources Culture & Careers Overview Xtraordinary Culture Current Openings Total Rewards Program Corporate Amenities Home Terms of use Privacy policy Disclaimer for Twitter